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a b s t r a c t
Tourette syndrome (TS) is a highly heritable yet heterogeneous childhood onset disorder. The cardinal
movement disorder required for diagnosis is tics. As persons with tics or TS often have obsessive/
compulsiveness, inattention, hyperactivity, impulsivity, anxiety, and anger outbursts, the presence of tics
should prompt clinicians to look for these other conditions. While randomized controlled trials provide
valid evidence of efﬁcacy for symptoms in isolation, implications for treatment of complex patients
meeting criteria for multiple diagnoses is not always clear. In this review, the authors critically review
factors inﬂuencing decisions whether and how to treat medically tics as well as OCD and ADHD in the
presence of tics.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Tics, the cardinal symptom of Tourette syndrome (TS), are
patterned involuntary, “unvoluntary” (compelled by inner urge),
or habitual movements (motor tics) or sounds (phonic tics), often
preceded by a premonitory sensation (Dooley, Gordon, Wood,
Camﬁeld, & Camﬁeld, 2003; Jankovic, 2001; Kurlan, 2010;
Kompoliti & Goetz, 1998). The premonitory phenomenon helps
in differentiation of tics from other jerk-like movements such as
myoclonus and chorea, which occur without preceding urges
(Kwak, Dat Vuong, & Jankovic, 2003; Woods, Piacentini, Himle, &
Chang, 2005). Tics are quite common in otherwise normally
developing children (Snider, Seligman, & Ketchen, 2002) and are
approximately twice as common in children receiving special
education services as those who are mainstreamed (Kurlan,
1994; Kurlan, Como, & Miller, 2002; Kurlan, Whitmore, Irvine,
McDermott, & Como, 1994; Palumbo, Maughan, & Kurlan, 1997).
Although generally considered childhood disorders, tics can
persist into adulthood, but usually with lower frequency and reduced
intensity (Bloch & Leckman, 2009; Bloch, Peterson, & Scahill, 2006;
Leckman, Zhang, & Vitale, 1998; Pappert, Goetz, Louis, Blasucci, &
Leurgans, 2003). Adult onset tics usually represent re-emergence of
childhood onset tics, but other causes of tics besides TS, such as drugs
(e.g. CNS stimulants, cocaine, neuroleptics), Huntington disease,
neuroacanthocytosis, autism, and other neurological disorders should
be considered as possible etiologies. Most clinical trials and studies
address treatment of tics in childhood, but some, particularly studies
of new medications or other treatments, include or focus on adults
(Chae, Nahas, & Wassermann, 2004; Gilbert, Budman, Singer, Kurlan,
& Chipkin, 2014; Jankovic, Jimenez-Shahed, & Brown, 2010; Okun,
Foote, & Wu, 2013; Scahill, Leckman, Schultz, Katsovich, & Peterson,
2003; Wilhelm, Peterson, & Piacentini, 2012).
Achieving the most effective treatment of tics in TS is con-
tingent on proper diagnosis of the movement disorder and
judicious use of available interventions. In many cases, no medica-
tion is needed and simple reassurance will sufﬁce. When medica-
tion is prescribed, the goal is to reduce the tic frequency and
intensity so that the tics no longer impair the patient's function at
home, school, or at work, and no longer interfere with social
activities and interactions. Achieving the most effective and safest
treatment of the child or adult with TS requires thorough assess-
ment and treatment for other cognitive and emotional problems
(Carter et al., 2000; Gilbert, 2006; Singer, 2005; Zinner, 2004).
Effective pharmacologic treatment is aided by collaborative, rea-
listic assessment with the individual and family of tic-related and
comorbidity-related impairment.
Treatment of tics in TS has been the subject of a number of
excellent review articles (Jankovic & Kurlan, 2011a; McNaught &
Mink, 2011; Wu, Harris, & Gilbert, 2010). These reviews include
guidelines for medication selection, dosing, and monitoring for side
effects. In this paper wewill focus our review on oral pharmacological
treatment for tic, ADHD, and OCD symptoms in TS but also discuss
more broadly the issues inﬂuencing treatment decisions. In addition
to oral medications, many patients with TS manifested chieﬂy by focal
tics, such as blinking and cervical tics, may be treated with local
injections of botulinum toxin (Kwak, Hanna, & Jankovic, 2000;
Marras, Andrews, Sime, & Lang, 2001). This approach is particularly
effective in the treatment of repetitive head jerking (so called
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/jocrd
Journal of Obsessive-Compulsive and Related Disorders
http://dx.doi.org/10.1016/j.jocrd.2014.04.006
2211-3649/& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
n Corresponding author. Tel.: þ1 513 636 4222; fax: þ1 513 636 1888.
E-mail address: donald.gilbert@cchmc.org (D.L. Gilbert).
Journal of Obsessive-Compulsive and Related Disorders 3 (2014) 407–414
“whiplash” tics), that can cause secondary myelopathy, and other
potentially disabling tics (Dobbs & Berger, 2003; Krauss & Jankovic,
1996; Lin, Wang, Wong, Wu, & Lin, 2007; Muroi et al., 2002). Some
tics are so severe and even life-threatening (hence the term “malig-
nant TS”) (Cheung, Shahed, & Jankovic, 2007) that they cannot be
managed medically and in such cases deep brain stimulation may be
considered (Mink, Walkup, & Frey, 2006). This therapeutic interven-
tion is beyond the scope of this review and is covered elsewhere in
this volume.
2. Treatment of the non-tic symptom spectrum in TS
2.1. Who should treat TS and its comorbidities?
An important treatment issue in TS is where to seek treatment
if the primary care physician and/or patient desire specialty care.
Often in persons with TS, cognitive, behavioral and emotional
problems cause far more impairment than tics (Bernard, Stebbins,
& Siegel, 2009; Carter et al., 2000). In both community and clinic
settings, the majority of children and adults with tics or TS also
have troublesome non-tic problems including symptoms of Atten-
tion Deﬁcit Hyperactivity Disorder (ADHD), Obsessive Compulsive
Disorder (OCD), other forms of anxiety, substance abuse, aggres-
sion, or anger control difﬁculties (Comings, 1994; Freeman, 2007;
Kurlan et al., 2002; Zinner, 2004). Genetic studies also clearly
demonstrate high rates of these same problems in families of TS
probands, including both parents (“bilineal transmission”) and
even in family members who do not have tics (Comings &
Comings, 1990; Grados & Mathews, 2008). Children diagnosed
with autistic spectrum disorders often present with tics and may
meet criteria for TS (Canitano & Vivanti, 2007; Comings &
Comings, 1991; Lawson-Yuen, Saldivar, Sommer, & Picker, 2008).
Thus whether we consider ADHD or OCD “comorbidities” of TS or
manifestations within the spectrum of a heterogeneous neurobe-
havioral disorder, physicians involved in the management of
patients with TS must be skilled in not only treating tics but the
entire spectrum of symptoms that commonly affect patients
with TS.
The roles of neurologists and psychiatrists have traditionally lead
to fractionated care, particularly when the mental health diagnoses
receive different (less) reimbursement by health insurance companies
which prioritize medical (neurological) over mental health coverage.
However, there are a number of other disorders in which neurological
and psychiatric symptoms commonly co-exist. In addition to TS, other
examples of such overlap include the adult and childhood epilepsies
(Brodie, Chadwick, & Anhut, 2002; Franks, 2003; Hesdorffer et al.,
2004), multiple sclerosis (Patten, Fridhandler, Beck, & Metz, 2003;
Patten & Metz, 1997), cerebrovascular diseases (O’Brien, Erkinjuntti, &
Reisberg, 2003; Robinson, 2003; Taragano, Allegri, Vicario, Bagnatti, &
Lyketsos, 2001), Parkinson's disease (Klaassen et al., 1995; Mindham,
Marsden, & Parkes, 1976), tardive dyskinesia (Klaassen et al., 1995),
and Huntington's disease (Bonelli, Wenning, & Kapfhammer, 2004).
Thus in these and many other neurological conditions, neurologists
should be skilled in managing the associated behavioral or psychiatric
problems. Given the high prevalence of movement disorders in
psychiatric patients, it is similarly reasonable for psychiatrists to feel
some level of comfort with diagnosis and evaluation of movement
disorders. In many cases, the best approach is for these disciplines to
work collaboratively with multiple specialties to provide the most
comprehensive and expert care.
With these considerations in mind, clinicians who see large
numbers of TS patients should be prepared to treat non-tic
symptoms of TS. A reasonable expectation might be that neurolo-
gists providing or directing fairly comprehensive care for TS would
treat ADHD and OCD in many cases, but refer to psychiatrists those
TS patients manifesting severe OCD, psychosis, auditory hallucina-
tions, mania, and suicidal ideation. Similarly, psychiatrists treating
TS would treat tics in many cases, but might refer to neurologists
patients demonstrating particularly severe tics, suspected seizures,
drug induced movement disorders, suspected secondary tic dis-
orders, or progressive cognitive impairment.
2.2. Evidence-based treatment of ADHD in persons with TS
Most double blind, randomized, placebo-controlled clinical
trials of treatments for behavioral diagnoses attempt to recruit a
relatively pure sample of individuals whose impairing symptoms
emanate from the primary diagnosis. Thus, subjects who suffer
from other DSM-V diagnoses are typically excluded, particularly if
these other diagnoses are severe enough to require current
treatment. In the cases of conditions like TS, where meeting
criteria for two or more DSM-V diagnoses is the rule rather than
the exception, this practice favors validity at the expense of
generalizability (Gilbert & Buncher, 2005). As most studies have
been small, and the majority of large, rigorous clinical trials of
ADHD and OCD treatment exclude TS, it is difﬁcult to know
whether estimates of effect size in clinical trials are generalizable
to TS in the community. Furthermore, while the practice of
evidence-based medicine is encouraged, it is important to
acknowledge that most patients with TS referred to a specialty
clinic would be excluded from the controlled trials that provide
“the evidence”.
Treatment of ADHD in TS is more complicated than treatment
of ADHD without co-occurring TS, for at least two main reasons.
First, in some individuals with TS, tics or other repetitive behaviors
may worsen when stimulant medications are prescribed for
ADHD. That is, even when inattention, hyperactivity, and impulse
control problems reliably and reproducibly diminish on stimu-
lants, tics, compulsions, or stereotypies can concurrently escalate,
often in a dose-sensitive (Bloch, Panza, Landeros-Weisenberger, &
Leckman, 2009) fashion. While observed by clinicians for many
years, this stimulant-induced exacerbation is not a universal
occurrence and indeed may be quite uncommon (Denckla,
Bemporad, & MacKay, 1976; Tourette Syndrome Study Group,
2002). In such cases, a more beneﬁcial outcome may be achieved
with nonstimulants for ADHD, such as atomoxetine, or combining
a stimulant with an alpha 2 adrenergic agonist or a dopamine
receptor blocking agent or tetrabenazine. Indeed, when patients
present with the combination of troublesome tics and ADHD we
often treat the tics ﬁrst and add a stimulant later. This strategy
should be carefully explained to the patients and their parents,
particularly those who (often incorrectly) perceive this risk of
stimulants outweighing their potential beneﬁts. A second impor-
tant challenge in TS is the potential for diagnostic misclassiﬁcation
of both inattention and hyperactivity symptoms of ADHD. In TS
with anxiety, OCD, or high functioning autism, sometimes what
appears by observation or standardized DSM-V based ratings
(Conners, Sitarenios, Parker, & Epstein, 1998; DuPaul, Power,
Anastopoulos, & Reid, 1998; Wolraich et al., 2003) to be a deﬁcit
in attention is actually wholly or in part a misdirection of attention
(“attention direction disorder”). The individual with TS, instead of
paying attention to what is salient to the rest of the classroom or
family, may attend to internal premonitory tic urges, poorly
ﬁltered sensations, obsessions, ruminations, or areas of special
interest. In such cases, treatment with a stimulant may increase
the child's internally directed focus. The result can be increased
tics, increased OCD symptoms, increased autistic behavior or
stereotypies, marked agitation, or what parents sometimes
describe as a “zombie” phenomenon where empathy is further
diminished and/or the child's spontaneity and creativity are
stultiﬁed. Clinical experience suggests that many such children
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are better off not taking stimulants or they may beneﬁt from
treatments directed against their OCD, anxiety, or other symptoms
that may interfere with their “attentiveness”. Similarly, care
should be taken to distinguish tics and stereotypies, which are
coordinated, repetitive and patterned movements, from the gen-
eral hyperkinesis and ﬁdgeting characteristic of ADHD-
hyperactivity. Although some complex tics may appear stereoty-
pic, recurrent or persistent stereotypies are more common in
patients with autistic spectrum disorder or some other neurobe-
havioral disorder other than TS. In rare cases, hyperkinesis may be
chorea, myoclonus, or some drug-induced movement disorder.
Suspicion of these movement disorders should generate a referral
to a movement disorder neurologist.
Interpreting clinical trial data also poses challenges. To achieve
an accurate estimate of TS effects on results of ADHD treatment
would require at a minimum, large, rigorous clinical trials in ADHD
which included a substantial number of individuals with TS.
Deriving an estimate by comparing results across separate non-
TS and TS studies would be confounded by other differences in
inclusion criteria, treatment practices, and the inherent inaccura-
cies in clinically assessing OCD and ADHD severity using subjective
rating scales. Moreover, a broadly representative TS sample would
not be recruited into placebo-controlled mono-therapy studies
because patients required pharmacologic treatment of ADHD and
OCD would be automatically excluded (Gilbert & Buncher, 2005).
The best estimates we have of treatment outcomes for child-
hood ADHD comes from the multimodal treatment of ADHD
(MTA) study, which compared, in 579, 7–9 year old children, four
regimens: (1) very intensive behavioral interventions provided by
experts, (2) stimulant medications prescribed by experts, (3) the
combination of these interventions, and (4) routine community
care. The MTA study showed that core ADHD symptoms were
effectively reduced by stimulants in most children and that these
beneﬁts persisted during active expert treatment over 14 months
(Multimodal Treatment of ADHD Cooperative Group, 1999). Unfor-
tunately, outcomes of all 4 groups converged over 3–8 years, with
persistent high rates of hospitalization for mental illness, sub-
stance abuse, and incarceration or involvement of the justice
system (Molina, Flory, & Hinshaw, 2007; Molina, Hinshaw, &
Swanson, 2009). No comparable, controlled, long-term studies
are available in TS. However, it is unlikely that a TS plus ADHD
cohort would have fared better than the children in the MTA study.
Thus, a take-home message for clinicians treating children with TS
plus ADHD is that there is a relatively high long-term risk of
adverse social outcomes. Nevertheless, most patients with the
combination of TS and ADHD achieve high quality of life when
properly managed by knowledgeable physicians.
With regard to short term beneﬁts of ADHD treatment, there
are a number of randomized, placebo-controlled trials of ADHD
treatment in children with tics or TS using stimulants (Castellanos,
Giedd, & Elia, 1997; Gadow, Nolan, Sverd, Sprafkin, & Schneider,
2008; Tourette Syndrome Study Group, 2002) and a selective
norepinephrine reuptake inhibitor (Allen, Kurlan, & Gilbert,
2005). Effects of these, along with ADHD treatments with guanfa-
cine, clonidine, deprenyl, and desipramine were combined in a
meta-analyses of nine double-blind, randomized, placebo con-
trolled studies of ADHD treatment in TS (Bloch et al., 2009). A main
aim of these studies was to see if ADHD could be effectively
treated without making tics worse. Taken together, the results of
these studies show that stimulants, alpha-2 adrenergic agonists,
and norepinephrine reuptake inhibitors are more effective than
placebo in reducing ADHD symptoms in children with TS. In
addition, in the two largest studies, for most participants on active
treatment with methylphenidate, clonidine, or atomoxetine, tics
improved (Allen et al., 2006; Tourette Syndrome Study Group,
2002). Thus, stimulants as well as other pharmacologic treatments
are quite effective in the treatment of ADHD and are usually not
contraindicated in the presence of TS. In patients with ADHD who
also have co-existent troublesome tics it is considered prudent
practice to treat the tics ﬁrst (see below) before initiating anti-
ADHD therapies.
2.3. Evidence-based treatment of OCD in persons with TS
Estimating OCD treatment outcomes in TS involves the same
obstacles discussed above for ADHD. However, treatment of OCD
in the presence of tics has been even less systematically investi-
gated. Based on a small post-hoc analysis, it appears that both
cognitive behavioral therapy and selective serotonin reuptake
inhibitors (SSRIs) are less effective in OCD with tics than in OCD
with no tics (Garcia, Sapyta, & Moore, 2010; The Pediatric OCD
Treatment Study (POTS) Team, 2004).
The best estimates we have of treatment outcomes for child-
hood OCD comes from the pediatric obsessive compulsive disorder
treatment study (POTS), which compared, in 112 children, 7–17
year old, four regimens: (1) very intensive cognitive behavioral
therapy (CBT) provided by experts, (2) selective serotonin reuptake
inhibitor medication prescribed by experts, (3) the combination of
these interventions, and (4) placebo (The Pediatric OCD Treatment
Study (POTS) Team, 2004). The POTS study showed that active
treatments reduced OCD symptoms at 12 weeks. However, a more
clinically useful take home message from the study is the propor-
tion of individuals in each group who achieved an excellent
outcome: 3% in the placebo group; 21% in the sertraline group;
39% in the CBT group, and 54% in the combined treatment group.
Although these short-term outcomes seem disappointing, indivi-
dualized approach using different combinations of behavioral and
pharmacologic therapies, often provides satisfactory relief of
symptoms (Scahill, Erenberg, & Berlin, 2006). The current expert
consensus is that the pharmacological treatment of choice for OCD
with TS is the same as for OCD without TS: SSRIs, or clomipramine.
A better outcome however may be achieved with concurrent
cognitive behavioral therapy.
3. Treatment of the tic symptom spectrum in TS
3.1. When to treat tics?
The ﬁrst decision point for treatment interventions for move-
ment disorders is to recognize the phenomenology of the domi-
nant movement disorder. Phenomenology is the basis for the
selection of the most appropriate therapeutic option. Thus tics
generally respond to different treatments than other hyperkinetic
movement disorders such as dystonia or myoclonus, or psycho-
genic movement disorders that may resemble tics. The next step is
to decide whether the movement disorder is troublesome enough
to require treatment at all. It is important to recognize that there
are no preventive or disease modifying therapies for any of the
movement disorders. However, currently available symptomatic
treatments, when properly selected and applied, can provide at
least partial beneﬁts. The indications for consideration of medical
treatment should be the presence of (1) social impairment
(including classroom or workplace disruption due to phonic tics),
(2) functional impairment, (3) pain, or (4) neurological or other
deﬁcit as a result of the tics (or self-injurious behavior) (Cheung et
al., 2007). Even when none of these four criteria are met,
individuals or families may still request treatment if tics are
annoying. Conversely, even when one or more of these criteria
are met, some individuals or parents will chose not to treat due to
their perceptions that the potential beneﬁts do not outweigh the
possible risks. This scenario poses signiﬁcant difﬁculties for both
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patients and care-providers as the parents' perceptions may be
irrational and not in the best interest of the child. An emerging
area of research involves understanding more systematically the
reported differences between parent and children in tic and non-
tic related impairment in TS (Cavanna, Luoni, & Selvini, 2013;
Termine, Luoni, & Selvini, 2014). In addition to pharmacologic
therapies consideration should be given to non-medical (e.g.
behavioral or surgical) treatment options (Piacentini, Woods, &
Scahill, 2010; Piacentini et al., 2010).
3.2. Three tiers of evidence-based pharmacological treatment tics
Once a decision to try medication for tics has been reached,
there are essentially three tiers of oral medications (Jankovic &
Kurlan, 2011b). The ﬁrst-tier medications are alpha 2 adrenergic
agonists guanfacine (Scahill, Chappell, & Kim, 2001) and clonidine
(Du, Li, & Vance, 2008; Leckman et al., 1991; Tourette Syndrome
Study Group, 2002). These agents are relatively well tolerated
except for sedation, lightheadedness, and dry mouth as the most
common side effects. Both can improve ADHD symptoms, but the
authors use them more frequently for the treatment of impulse
control disorder (Palumbo et al., 2008; Sallee, Lyne, Wigal,
McGough, 2009; Sallee et al., 2009; Tourette Syndrome Study
Group, 2002). Clonidine may be more helpful for sleep initiation at
night, but daytime sedation limits its use (Tourette Syndrome
Study Group, 2002). Both can also be readily combined with
psychostimulants (Tourette Syndrome Study Group, 2002). It is
reasonable in many cases for primary care physicians to initiate
treatment with guanfacine or clonidine, subsequently referring
cases which are refractory.
The second tier oral, tic-suppressing medications includes a
plethora of medications which appear, usually in small or open
label studies, to have modest beneﬁt. Some of these have been
used off-label for decades (Robertson, 2000). Effects of these
medications tend to be modest, but some may be chosen in order
to concurrently treat tics plus another symptom. Sometimes the
motivation for using these medications is to avoid the third tier,
the dopamine receptor blocking agents, whose risks are more
intimidating for individuals and families. Topiramate, an antic-
onvulsant, has been found in one double-blind, placebo-controlled
trial to effectively reduce tics (Jankovic et al., 2010). Although not
all patients can tolerate this drug and some develop cognitive and
other adverse effects, it can be helpful particularly if patients
would also beneﬁt from migraine prophylaxis (Lewis, Winner, &
Saper, 2009). Results for the anticonvulsant levetiracetam have
been mixed (Awaad, Michon, & Minarik, 2005; Hedderick, Morris,
& Singer, 2009; Smith-Hicks, Bridges, Paynter, & Singer, 2007). The
use of dopamine agonists pergolide (no longer marketed) (Gilbert
et al., 2003) and ropinirole (Anca, Giladi, & Korczyn, 2004) for tics
initially appeared promising, but a controlled trial of pramipexole,
another dopamine agonist, showed no beneﬁt (Kurlan et al., 2012).
The third tier medications include the anti-dopaminergic drugs,
either dopamine receptor blocking agents, also known as neuroleptics
or antipsychotics, or dopamine depletors, such as tetrabenazine. Only
two medications are currently approved by the United States Food
and Drug Administration for tic suppression in TS: haloperidol and
pimozide. In addition to these two agents, a number of other
dopamine receptor blocking agents have been used successfully to
treat tics. There are, however, only a few head-to-head comparisons
of these agents. In general, the typical agents pimozide, haloperidol,
and ﬂuphenazine, and the high potency atypical agent risperidone
appear comparable (Bruggeman et al., 2001; Gilbert, Batterson, &
Sethuraman, 2004; Rose & Moldofsky, 1977; Sallee, Nesbitt, Jackson,
Sine, & Sethuraman, 1997; Singer, Gammon, & Quaskey, 1985;
Wijemanne, Wu, & Jankovic, 2013). However, there are a large
number of potential neurologic, cognitive, emotional, metabolic,
and cardiac side effects of this class of medications which limit their
use (Kompoliti, Goetz, Morrissey, & Leurgans, 2006). Of particular
concern is the risk of tardive movement disorders (Correll & Kane,
2007; Klaassen et al., 1995; Silva, Muñoz, Daniel, Barickman, &
Friedhoff, 1996; Wonodi, Reeves, & Carmichael, 2007). Fortunately,
this risk appears to be quite low in children with TS, but the risk is
greater in adult patients. Competent monitoring for emergence of
drug-induced movement disorders is critical.
The practice parameter for treatment of tics in TS published in
2006 by the Medical Advisory Board of the Tourette Syndrome
Association www.tsa-usa.org (Scahill et al., 2006) still provides
useful information on effect sizes for symptom suppression for
dopamine receptor blocking agents and other medications. Based
on trial design, the Advisory Board categorized medications into
three groups: A – those with short term safety and efﬁcacy
demonstrated in at least two randomized placebo-controlled
trials; B – those with short term safety and efﬁcacy demonstrated
in at least one placebo-controlled study; C – those supported by
clinical experience and open label studies. Levels of evidence from
the 2006 practice parameter, dose ranges, and monthly costs are
shown in Table 1. A meta-analysis estimating beneﬁcial effects of
pimozide was also published (Pringsheim & Marras, 2009). More
recently, a few small clinical trials have demonstrated beneﬁt in TS
from aripiprazole (Budman, Coffey, & Shechter, 2008; Seo, Sung,
Sea, & Bai, 2008; Yoo, Joung, & Lee, 2013) and metoclopramide
(Nicolson, Craven-Thuss, Smith, McKinlay, & Castellanos, 2005).
These drugs, similar to other neuroleptics, however, can cause a
variety of tardive syndromes (Kenney, Hunter, Davidson, &
Metoclopramide, 2008; Pena, Yaltho, & Jankovic, 2010, 2011),
although this still appears to be extremely rare in TS.
Although dopamine-receptor blocking drugs are among the
most effective anti-tic medications, because of concern about
weight gain and potential tardive complications, other drugs are
increasingly used in the treatment of tics, despite lack of rigorous
clinical trials. In patients with signiﬁcantly impairing tics, tetra-
benazine may also be considered. This is based both on the
mechanism of action, as well as on results of open label studies
performed over many years (Jankovic, 2009; Kenney, Hunter,
Mejia, & Jankovic, 2007; Paleacu et al., 2004; Sweet, Bruun,
Shapiro, & Shapiro, 1974). This dopamine-depleting drug has the
advantage over the dopamine receptor blocking agents in that it
does not cause tardive dyskinesia or weight gain, but it still can be
associated with some adverse effects, such as sedation, slowness
of movement, depression, akathisia and insomnia (Kenney et al.,
2007; Ondo, Jong, & Davis, 2008).
Clinical practice supports judicious use of medications when
tics cause impairment. Sequential monotherapy and starting with
a low dose at bedtime and titrating up slowly diminishes sedation
and other side effects. The aim is to ﬁnd the lowest tolerable dose
that satisfactorily reduces tics. Table 2 shows common medica-
tions and methods for titrating up on the dose. Discontinuing
medications after an adequate trial, or when symptoms seem to
have spontaneously remitted, should be done gradually, not
abruptly. Medications doses may also be reduced during less
stressful periods, e.g. summer vacations.
Costs may also inﬂuence decisions, particularly when families
have no health insurance or expensive co-pays (see Table 1). Thus
in the absence of head-to-head comparisons, one may choose
medications like topiramate and tetrabenazine for patients who
are overweight and avoid medications like risperidone and other
neuroleptics.
3.3. How do we know which medications work best for tics?
Evaluating tic outcomes in clinical trials and in clinical practice
is not straightforward (Gilbert & Buncher, 2005; Jeon, Walkup, &
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Woods, 2013). Tics wax and wane over minutes, hours, days, and
lifetime (Leckman et al., 1998; Peterson & Leckman, 1998;
Peterson, Pine, Cohen, & Brook, 2001), and individuals may choose
to enroll in a study or begin medication in practice during a time
when tics are at a maximum. Subsequent improvement may then
be medication-induced or may represent spontaneous remission
as part of the natural course of the disease rather than due to
treatment. As nearly all published trials in TS are short-term
studies, it is quite possible that long-term treatment beneﬁts are
overestimated. In one long-term, open-label study involving 268
patients with TS, ﬂuphenazine at an optimal dose of 3.2472.3 mg/
day (range 0.5–12 mg/day), continued to provide beneﬁt for an
average of 2.673.2 years (range 0.01–16.8 years) (Sallee et al.,
1997). Commonest side effects included drowsiness, fatigue or
both, observed in 70 (26.1%) of patients, but there were no cases of
tardive dyskinesia.
As is the case for other movement disorders, rating scales are
used in clinical trials and often in practice. The rating scale most
often used for tics in TS is the Yale Global Tic Severity Score
(YGTSS) (Leckman, Riddle, & Hardin, 1989). In clinical trials, the
primary treatment outcomes may be either the total YGTSS, which
includes a subjective 0–50 point metric of tic impairment, or the
0–50 point total tic scale only, which is less subjective but does not
capture global life-impairment effects. The YGTSS tic-only scores
capture the phenomenology, with 5 points each for number,
frequency, intensity, complexity, interference, and separate scores
for motor vs. phonic tics.
It is important to note that the YGTSS is only a rough metric of
symptom severity and does not necessarily reﬂect an individual's
perceptions or a clinician's ratings of symptoms. For example, an
individual with both mild motor and mild phonic tics and not
interested in treatment could have a higher score than a person
with a current single very severe and impairing motor tic. Another
difﬁculty is that the 5 equally scored components are not likely to be
equally responsive to treatment or equally valued by patients. For
example, it may be more important to an individual to reduce the
frequency or severity of tics than to reduce the number or complexity
of them. A two point reduction in either frequency or severity might
be highly valued clinically despite the small effects statistically. A
meta-analysis modeling improvement in behavioral treatment trials
estimated that a 25% reduction in the YGTSS tic score corresponds to
a positive response in the clinical global impression scale. However,
meaningful global improvement may also occur in ways not captured
by the YGTSS tic score (Jeon et al., 2013).
Given the prevalence of non-tic symptoms, perhaps a TS
composite score might be considered. Such a score might be helpful
if more basic, upstream neurobiological mechanisms in TS are
identiﬁed through research and targeted by novel treatments that
simultaneously reduce multiple symptoms. Such a scale would be
difﬁcult to develop and interpret and would have little added value
over current practice in clinical trials, where symptom domains are
rated on separate rating scales. Thus in interpreting the results of a
study for patient care, it is prudent to look at not only at the
primary outcome but secondary effects seen in other rating scales.
Global measures of function and improvement can also aid in
interpreting the usefulness of an agent in a clinical trial. A
signiﬁcant global beneﬁt in a placebo controlled trial may be
important, even if the tic score does not register much change.
As has been reviewed elsewhere (Cubo, Gonzalez, & Singer,
2013; Gilbert, 2006; Gilbert & Buncher, 2005), a few additional
caveats are in order related to study design. Uncontrolled, open
label studies often overestimate beneﬁt because many non-drug
factors may inﬂuence the outcome. However, they may also be
able to recruit more severely affected patients and may allow
treatment of co-occurring symptoms. Also, long-term observa-
tional trials more closely approximate the “real-life” situationTa
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when patients with multiple symptoms are often treated with
multiple medications. Placebo-controlled studies, while desirable
to generate evidence-based data and valid assessments of treat-
ment effects, have their own limitations in that they are usually
short, inﬂexible, and the results may not be generalizable as the
enrollment is available only to those who meet strict inclusion–
exclusion criteria. A recent study of placebo controlled trials in TS
estimated a tendency toward improvement on placebo which
approached statistical signiﬁcance but had a small effect size
(Cohen's d¼0.16) (Cubo et al., 2013). Furthermore, both patient
concerns about placebo and requirements for monotherapy may
reduce willingness of severely affected individuals to participate,
particularly if the agent being studied is already marketed and can
be more easily obtained through routine clinical care. Therefore,
the results of clinical trials, whether placebo controlled, active
comparator, or open label may have value but should be applied
cautiously to the general population of TS patients.
There are many other emerging or experimental treatment
approaches that may be eventually incorporated into the therapeutic
armamentarium in TS. These include: (1) Cannabinoids, such as
delta9-tetrahydrocannabinol (Curtis, Clarke, & Rickards, 2009); (2)
AZD5213 (novel histamine H3 receptor inverse agonist) (Jucaite,
Takano, & Bostrom̈, 2012); (3) Ecopipam (a D1 antagonist) (Gilbert
et al., 2014); (4) SD-809 ER (a deuterated form of tetrabenazine)
(Jimenez-Shahed & Jankovic, 2013); (5) forms of repetitive transcra-
nial magnetic stimulation (Kwon, Lim, & Lim, 2011; Wu, Maloney, &
Gilbert, 2014); (6) novel surgical approaches (Viswanathan, Jimenez-
Shahed, Baizabal Carvallo, & Jankovic, 2012); and other novel
therapeutic interventions (Termine, Selvini, Rossi, & Balottin, 2013).
4. Summary
TS is a complex disorder with many symptoms which may
beneﬁt from education, behavioral training, medical treatment,
and sometimes more invasive treatments. Treatment requires a
thoughtful approach to the full spectrum of problems, focusing on
impairment. Education and collaboration with the individual and
family is essential. Current medical treatments have suboptimal
effectiveness, and clinical trial literature, while useful, should be
interpreted thoughtfully. Advocacy groups like the Tourette Syn-
drome Association offer many useful resources to patients,
families, schools, and treating professionals which may also
mitigate the impairment from TS symptoms.
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